Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity
/in Dendritic Cells, International PublicationsComparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients
/in Dendritic Cells, Glioblastoma, International PublicationsCurrent status of immunotherapy for the treatment of biliary tract cancer
/in Dendritic Cells, Gallbladder Cancer, International PublicationsVaccine strategies for glioblastoma: progress and future directions
/in Dendritic Cells, Glioblastoma, International PublicationsAutologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancerα-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
/in Dendritic Cells, Glioblastoma, International PublicationsThe immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
/in Dendritic Cells, International Publications, Malignant MelanomaEnhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma
/in Dendritic Cells, International Publications, Malignant LymphomaTargeting cancer stem cells via dendritic-cell vaccination
/in Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer